STOCK TITAN
  1. Home
  2. Sec-filings
  3. EVGN
  4. [EFFECT] Evogene Ltd. SEC Filing

[EFFECT] Evogene Ltd. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: November 19, 2025
Accession Number: 0001178913-25-003429
Submission Type: POS AM
CIK: 0001574565
Company Name: Evogene Ltd.
File Number: 333-282218

Source: View Original Filing on SEC EDGAR

Stock EVGN logo
Evogene

NASDAQ:EVGN

EVGN Rankings

#6501 Ranked by Market Cap
N/A Ranked by Dividends

EVGN Latest News

Feb 25, 2026
Evogene Releases CEO Letter to Shareholders
Feb 19, 2026
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release
Feb 17, 2026
Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics
Feb 11, 2026
Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases
Feb 10, 2026
Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds

EVGN Latest SEC Filings

Feb 25, 2026
[6-K] Evogene Ltd. Current Report (Foreign Issuer)
Feb 11, 2026
[6-K] Evogene Ltd. Current Report (Foreign Issuer)
Feb 4, 2026
[6-K] Evogene Ltd. Current Report (Foreign Issuer)
Jan 15, 2026
[6-K] Evogene Ltd. Current Report (Foreign Issuer)
Nov 20, 2025
[6-K] Evogene Ltd. Current Report (Foreign Issuer)

EVGN Stock Data

7.65M
8.63M
Biotechnology
Healthcare
Link
Israel
Rehovot